FDA - Adverse Event Reporting System (FAERS)



Similar documents
Clinical Implementation of Psychiatric Pharmacogenomic Testing

Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER

MOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Clinical Implementation of. Pharmacist-Managed Service. Kristine R. Crews, Pharm.D., BCPS St. Jude Children s Research Hospital

What is Pharmacogenomics? Personalization of Medications for You! Michigan State Medical Assistants Conference May 6, 2006

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Recognizing and Treating Depression in Children and Adolescents.

Clinical Audit: Prescribing antipsychotic medication for people with dementia

Update and Review of Medication Assisted Treatments

Seniors and. Depression. What You Need to Know. Behavioral Healthcare Options, Inc.

Reduced Risk & Improved Efficacy through Integrated Pharmacogenetics

Dual Diagnosis. Dual Diagnosis Good Practice Guidance, Dept of Health (2002);

Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance

Post-Traumatic Stress Disorder (PTSD)

Topic Area - Dual Diagnosis

Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations

BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC FAX

Revised 7/05. Copyright 2005 St. Jude Children's Research Hospital Page 1 of 6

Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form

Emergency in the Psychiatric

California Society of Addiction Medicine (CSAM) Consumer Q&As

MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

Alcohol Disorders in Older Adults: Common but Unrecognised. Amanda Quealy Chief Executive Officer The Hobart Clinic Association

SECTION N: MEDICATIONS. N0300: Injections. Item Rationale Health-related Quality of Life. Planning for Care. Steps for Assessment. Coding Instructions

SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE

REFERRAL FORM FOR ADMISSION TO HOMEWOOD HEALTH CENTRE

Post-Traumatic Stress Disorder (PTSD)

Depression is a common biological brain disorder and occurs in 7-12% of all individuals over

Overview of the Adverse Childhood Experiences (ACE) Study. Robert F. Anda, MD, MS Co-Principal Investigator.

Rekindling House Dual Diagnosis Specialist

Post-Traumatic Stress Disorder (PTSD)

HIV, High Dose Methadone, and the Treatment Conundrum 5/8/2014. Frederick L. Altice, MD, MA

A Pilot Study of the Incidence of Exposure to Drugs for which Preemptive Pharmacogenomic Testing Is Available

TREATING MAJOR DEPRESSIVE DISORDER

J. David Kinzie, M.D., FAC Psych. Professor of Psychiatry Oregon Health & Science University

Naltrexone and Alcoholism Treatment Test

Dual Diagnosis. Dr John Dunn Associate Clinical Director for Substance Misuse & Forensic Services Camden & Islington NHS Foundation Trust

BENZODIAZEPINE CONSIDERATIONS IN WORKERS COMPENSATION: IMPLICATIONS FOR WORK DISABILITY AND CLAIM COSTS By: Michael Erdil MD, FACOEM

Drugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement

Insomnia affects 1 in 3 adults every year in the U.S. and Canada.

FACTSHEET: DUAL DIAGNOSIS

Implementation of Pharmacogenomics in Clinical Practice: Barriers and Potential Solutions

placebo-controlledcontrolled double-blind, blind,

MEDICATION GUIDE. Bupropion Hydrochloride (bue-proe-pee-on HYE-droe-KLOR-ide) Extended-Release Tablets, USP (SR)

Depression Support Resources: Telephonic/Care Management Follow-up

Update on guidelines on biological treatment of depressive disorder. Dr. Henry CHEUNG Psychiatrist in private practice

Alcohol Addiction. Introduction. Overview and Facts. Symptoms

COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014

Low dose naltrexone as a treatment for multiple sclerosis

Managing potential drug-drug interactions to achieve success in HCV triple therapy. David Back University of Liverpool

NICE Clinical guideline 23

Desvenlafaxine Degradation

Drug Abuse and Addiction

Not All Clinical Trials Are Created Equal Understanding the Different Phases

Health Information Sheet

Cocaine. Like heroin, cocaine is a drug that is illegal in some areas of the world. Cocaine is a commonly abused drug.

Nursing 113. Pharmacology Principles

How To Stop A Pregnant Addict From Getting A Jail Sentence For Drug Use

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)

1. According to recent US national estimates, which of the following substances is associated

Questions & Answers About OCD In Children and Adolescents

Blueprint for Prescriber Continuing Education Program

Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)

ARE YOU PREPARED TO HELP YOUR TEEN MAKE GOOD DECISIONS? STATS, FACTS & TALKING POINTS ABOUT ALCOHOL AND OTHER DRUGS PARENT ACTION PACK

Adult Information Form Page 1

Alcohol Dependence and Motivational Interviewing

How To Treat A Drug Addiction

REPORTING A CRIME SUPPORT FOR VICTIMS ALCOHOL ANTI-SOCIAL BEHAVIOUR DRUGS & THE LAW OFFENSIVE WEAPONS STOP AND SEARCH

Alcohol and Brain Damage

North of Tyne Area Prescribing Committee

Depression. Introduction Depression is a common condition that affects millions of people every year.

F r e q u e n t l y As k e d Qu e s t i o n s

2. The prescribing clinician will register with the designated manufacturer.

Minimum Information Model for Reporting

Desvenlafaxine Succinate Er

the facts about NALTREXONE

ADULT INTAKE QUESTIONNAIRE. Today s Date: Home phone: Ok to leave message? Yes No. Work phone: Ok to leave message? Yes No

Treating Depression to Remission in the Primary Care Setting. James M. Slayton, M.D., M.B.A. Medical Director United Behavioral Health

The Global Relief Association for Crises & Emergencies G.R.A.C.E. COUNSELING INTAKE FORM

Depression & Multiple Sclerosis

Elements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits

Federal Act on Human Genetic Testing (HGTA) Scope, Purpose and Definitions

Methamphetamine. Like heroin, meth is a drug that is illegal in some areas of the world. Meth is a highly addictive drug.

Conjoint Professor Brian Draper

Medication Guide LATUDA (luh-too-duh) (lurasidone hydrochloride) Tablets

Integration of genomic data into electronic health records

Depression & Multiple Sclerosis. Managing Specific Issues

How To Use Naltrexone Safely And Effectively

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

Mental Health Needs Assessment Personality Disorder Prevalence and models of care

Are You Considering Medication for Depression?

Smoking Cessation and Mental Health: A briefing for front-line staff

A Depression Education Toolkit

Transcription:

FDACDER3090 Case Information: Case Type: EXPEDITED (15- DAY) esub: Y HP: Country: AUS Outcomes: OT, (A)NDA/BLA: 014685 / FDA Rcvd Date: 25-Aug-2014 Mfr Rcvd Date: 16-Mar-2012 Mfr Control #: AU-RANBAXY-2012R1-53740 Patient Information: Age: 35 YR Sex: Female Weight: Suspect Products: # Product Name 1 Nortriptyline Hydrochloride Dose/ Frequency Route Dosage Text Indications(s) Start Date End Date 12.5 MG/QD Unknown 12.5 mg, Daily Mental disorder 2 # 1 Valerian Unknown UNK Product used for unknown indication Interval 1st Product Name Dose to Event DeC ReC Lot# Exp Date NDC # MFR/Labeler Nortriptyline Hydrochloride U RANBAXY 2 Valerian A Event Information: Preferred Term ( MedDRA Â Version: Akathisia Delirium Drug interaction Homicide Suicidal ideation 17.0 ) ReC Print Time: 06-OCT-2015 08:02 PM If a field is blank, there is no data for that field Page 1 of 26

FDACDER3091 Event/Problem Narrative: This case, manufacturer control number 2012R1-53740 from AUSTRALIA refers to a 35 year old female with the following events (Preferred Terms): Akathisia and Homicide,Suicidal ideation and Delirium. This case was deemed serious as the reported events were considered to be medically significant. This case was reported in literature. The literature report consists of 10 case reports and this case refers to Patient of 10. ø¾ The patient received following medications which were considered as suspects: #1) Nortriptyline (Company suspect product) 12.5mg/day for psychological distress Therapy start date/stop date: Unknown Action taken: Withdrawn #2) Valerian for unknown indication Dose and frequency: Unknown Therapy start date/stop date: Unknown Action taken: Withdrawn As per the report, eleven patients were identified in a study after developing severe akathisia during treatment with antidepressants for psychological distress and various other drugs [some drug details not stated]; they subsequently became suicidal and/or committed or attempted homicide. All were found to have variant CYP450 alleles. All patients recovered from akathisia on withdrawal of the suspect drugs. A 35-year-old woman started receiving nortriptyline 12.5 mg/day; she had also been taking small doses of valerian for 1 month. Adding nortriptyline to valerian caused a toxic delirium. She developed severe akathisia and became suicidal, then committed homicide after 3 days. The outcome of the event 'Akathisia' was reported as 'resolved' and the outcome of the event 'Homicide, Suicidal ideation and Delirium' were reported as 'unknown' at the time of this report. Case outcome: Unknown The case is deemed serious. Medical Reviewer considered the case to be possibly related to suspect drug due to its temporal association as per WHO UMC system for standardized causality assessment. F/U#1: 16-Mar-2012 (Significant) Print Time: 06-OCT-2015 08:02 PM If a field is blank, there is no data for that field Page 2 of 26

FDACDER3092 A follow up was received to the case with following significant informations as: # Authors details were updated. # Dechallenge for Nortriptyline (company suspect product) was updated to "Positive" from "Unknown" # Following event (PT) was added 1) Drug interaction with outcome as 'Resolved' # Outcome of the events (PT) "Homicide, Suicidal ideation and Delirium" were updated to "Resolved" from "Unknown" As per follow up report, Table 3. Information on subject's drug regimens, CYP 450 genotypes, criminal facts and outcomes for ten of those suffering violant akathisia # Subject number: # Age; 35 # Gender: Female # Drug, dose and treatment duration: Nortriptyline (12.5 mg/day) superimposed on valerian # Reason for treatment : Treated for distress due to husband's drinking # Genotypes - # of null, diminished or ultrarapid metabolizer alleles: 2D6 *4/*41, 2C9 *1/*2, 2C19 *1/*17; One null allele, Two diminished alleles,one ultrarapid allele # Circumstances of crime: Killed daughter in toxic delirium after 3 days # Outcome: Pleaded mental illness, misdiagnosed with schizophrenia and treated with more CYP450 substrates. Recovered on withdrawal but more drugs are still being prescribed on Tribunal orders with near fatal consequences ø¾ ø¾ øê 'Subject øê (35-year-old female; genotypes: CYP2D6 *4/*41, CYP2C9 *1/*2, and CYP2C19 *1/*17) was prescribed a low dose of the 2D6-metabolized tricyclic antidepressant nortriptyline (12.5 mg/day) 3 days prior to committing homicide. She was severely impaired in metabolizing this drug owing to the 2D6 combination of *4 (null allele) and *41 (reduced activity allele). This subject also had reduced metabolism through 2C9 (*1/*2) and increased (ultrarapid) metabolism through 2C19 (*1/*17), although the significance of these genotypes for nortriptyline metabolism is unclear. ø¾ Subject, in her own words: Print Time: 06-OCT-2015 08:02 PM If a field is blank, there is no data for that field Page 3 of 26

FDACDER3093 My husband was drinking. I took small doses of valerian for a month and had. When I took nortriptyline, I immediately wanted to kill myself, talked myself out of it. I'd never had thoughts like that before. My husband was angry, shouting. I walked outside a lot, with palpitations, trouble breathing, and became more depressed. My smoking went up to 25 a day, no alcohol. I didn't sleep for two nights, dreamt, then slept maybe three hours, felt awful. I dreamt that I felt like a zombie. I believed I had to help my daughter,. I picked up a knife and stabbed her and woke up. I was not myself.. She said: " I realized what I'd done.., but the pills started again and thoughts of killing myself returned. Nortriptyline is extensively metabolized in the liver, primarily by hydroxylation. There is a strong correlation between total plasma clearance of nortriptyline and 2D6 enzyme activity. Reduced clearance resulting from this subject's 2D6 genotype alone would lead to a build up of serum nortriptyline, which has been shown to be associated with loss of efficacy, toxicity, and increased adversity in several studies. Nortriptyline is also significantly metabolized through 3A4 as an additional pathway, according to in vitro and in vivo data. In the case of severely reduced metabolism through 2D6, as in this subject, 3A4 would have been the major pathway for metabolism. However, the nortriptyline was superimposed on valerian, which has been shown to be a 3A4 inhibitor in vitro and to significantly increase the maximum serum levels of a 3A4 substrate in vivo. The addition of a substrate to an inhibitor is one drug-drug interaction scenario (Pattern 2), as described in Armstrong et al. The addition of nortriptyline to valerian immediately provoked a toxic delirium in this subject; she became akathisic and suicidal and 3 days later she committed the homicide. Conclusion : A detailed history and mental-state examination in these subjects presented here can exclude functional mental illness (which still has no biological markers) and confirm neurotoxicity. Pharmacogenetic evidence can assist with the rediagnosis of the population that causes the increased demand for mental health services. Restoring them to normality will reduce that demand and associated costs by taking pressure off ambulances, hospitals, prisons, and forensic wards. Akathisia homicides have been defended as instances of involuntary intoxication both with and without genetic evidence. Some perpetrators (and victims) succeed in receiving damages from the manufacturers for failure to warn. The Innocence Project examined evidence from crimes that took place before DNA testing was available. Personalized medicine in health care can bring about corresponding personalized justice in clinics, tribunals, courts and morgues." Case outcome: Resolved. Ranbaxy medical reviewers comment :~ ø¾ øê Print Time: 06-OCT-2015 08:02 PM If a field is blank, there is no data for that field Page 4 of 26

FDACDER3094 The case is deemed serious. Medical Reviewer considered the case to be possibly related to suspect drug due to its temporal association as per WHO UMC system for standardized causality assessment. Relevant Medical History: Disease/Surgical Procedure Start Date End Date Continuing? Medical History Product(s) Start Date End Date Indications Events Relevant Laboratory Data: Test Name Result Unit Normal Low Range Normal High Range Info Avail Concomitant Products: # Product Name Dose/ Frequency Route Dosage Text Indications(s) Start Date End Date Interval 1st Dose to Event Reporter Source: Study Report?: No Sender Organization: RANBAXY Print Time: 06-OCT-2015 08:02 PM If a field is blank, there is no data for that field Page 5 of 26

FDACDER3095 Literature Text: Lucire Y, Crotty. Antidepressant-induced Akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmacogenomics and Personalized Medicine. 2011;4(1):65-81 Print Time: 06-OCT-2015 08:02 PM If a field is blank, there is no data for that field Page 6 of 26